Kamada Analyst Ratings
Buy Rating Affirmed for Kamada on Accelerated Trial Prospects and Strong Financial Performance
Kamada Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Kamada Analyst Ratings
Promising Revenue Growth and Diverse Portfolio Drive Strong Buy Rating for Kamada: An Analysis by Andrew Fein
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL), Kamada (KMDA) and Mediwound (MDWD)
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Kamada Analyst Ratings
H.C. Wainwright Remains a Buy on Kamada (KMDA)
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Kamada (KMDA) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Kamada (KMDA) and Fate Therapeutics (FATE)
Kamada (KMDA) Receives a Buy from H.C. Wainwright
No Data